ELTX Earnings Elicio Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–26 of 26
| Q2 2026 | 2026-06-30 | -1.07 | 2026-08-13 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.65 | 2026-05-11 | 10-Q |
| FY 2025 | 2025-12-31 | -2.58 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -2.09 | 2025-11-13 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.50 | 2026-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.87 | 2026-05-11 | 10-Q |
| FY 2025 | 2024-12-31 | -4.25 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -3.23 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.77 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.15 | 2025-05-13 | 10-Q |
| FY 2024 | 2023-12-31 | -6.96 | 2025-03-31 | 10-K |
| Q3 2024 | 2023-09-30 | -6.75 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -9.65 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -24.77 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | -89.27 | 2024-03-29 | 10-K |
| Q3 2023 | 2022-09-30 | -68.52 | 2023-11-13 | 10-Q |
| Q2 2023 | 2022-06-30 | -45.85 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.48 | 2023-05-10 | 10-Q |
| FY 2022 | 2021-12-31 | -1.93 | 2023-03-17 | 10-K |
| Q3 2022 | 2021-09-30 | -2.51 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -2.02 | 2022-08-15 | 10-Q |
| Q1 2022 | 2021-03-31 | -1.56 | 2022-05-16 | 10-Q |
| FY 2021 | 2020-12-31 | -5.43 | 2022-03-30 | 10-K |
| Q3 2021 | 2020-09-30 | -3.51 | 2021-11-12 | 10-Q |
| Q2 2021 | 2020-06-30 | -2.32 | 2021-08-12 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.91 | 2021-05-17 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.